OPEN Journal of medical Internet research | 15 Jul 2015
J Lardon, R Abdellaoui, F Bellet, H Asfari, J Souvignet, N Texier, MC Jaulent, MN Beyens, A Burgun and C Bousquet
The underreporting of adverse drug reactions (ADRs) through traditional reporting channels is a limitation in the efficiency of the current pharmacovigilance system. Patients' experiences with drugs that they report on social media represent a new source of data that may have some value in postmarketing safety surveillance.
* Data courtesy of Altmetric.com